Effects of celecoxib on bcr-abl fusion protein in chronic myeloid leukemia primary cells / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 49-51, 2011.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-471863
Biblioteca responsável:
WPRO
ABSTRACT
Objective To explore the effects of celecoxib, a cyclooxygenase-2 (COX-2) specific inhibitor, on the mRNA expression protein expression and protein tyrosine kinase (PTK) activity of bcr-abl fusion gene in chronic myeloid leukemia (CML) primary cells. Methods The primary cells were incubated with various concentration of celecoxib (0, 10, 20, 40, 80, 160 μmol/L) for 36 hours, then the changes of mRNA expression, p210 expression and PTK activity of bcr-abl fusion gene in each group were examined respectively by real time quantitative reverse transcriptase polymerase chain reaction (RQ-RT-PCR), Western blotting and PTK activity analysis. Results The mRNA expression was downregulated with high concentration of celecoxib (80-160 μmol/L), and p210 expression was decreased gradually after increasing celecoxib. The PTK activity was inhibited in a concentration-independent way, and the statistic difference was observed only above 40μmol/L concentration of celecoxib. Conclusion Celecoxib can downregulate mRNA,and the protein expression of bcr-abl fusion gene; and inhibit the PTK activity by defferent extent.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2011
Tipo de documento:
Artigo